JP2008516922A - ヒスタミン受容体リガンドとしてのピロリジン誘導体 - Google Patents

ヒスタミン受容体リガンドとしてのピロリジン誘導体 Download PDF

Info

Publication number
JP2008516922A
JP2008516922A JP2007536122A JP2007536122A JP2008516922A JP 2008516922 A JP2008516922 A JP 2008516922A JP 2007536122 A JP2007536122 A JP 2007536122A JP 2007536122 A JP2007536122 A JP 2007536122A JP 2008516922 A JP2008516922 A JP 2008516922A
Authority
JP
Japan
Prior art keywords
alkyl
group
aryl
heteroaryl
prepared
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007536122A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008516922A5 (OSRAM
Inventor
ゴードン・ブルートン
イアン・ロナルド・クーパー
バリー・シドニー・オーレック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0423005A external-priority patent/GB0423005D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2008516922A publication Critical patent/JP2008516922A/ja
Publication of JP2008516922A5 publication Critical patent/JP2008516922A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
JP2007536122A 2004-10-15 2005-10-13 ヒスタミン受容体リガンドとしてのピロリジン誘導体 Withdrawn JP2008516922A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0423005A GB0423005D0 (en) 2004-10-15 2004-10-15 Novel compounds
GB0508441A GB0508441D0 (en) 2004-10-15 2005-04-26 Novel compounds
PCT/EP2005/011371 WO2006040192A1 (en) 2004-10-15 2005-10-13 Pyrrolidine derivatives as histamine receptors ligands

Publications (2)

Publication Number Publication Date
JP2008516922A true JP2008516922A (ja) 2008-05-22
JP2008516922A5 JP2008516922A5 (OSRAM) 2008-11-27

Family

ID=35583486

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007536122A Withdrawn JP2008516922A (ja) 2004-10-15 2005-10-13 ヒスタミン受容体リガンドとしてのピロリジン誘導体

Country Status (13)

Country Link
US (1) US20080045506A1 (OSRAM)
EP (1) EP1802307B1 (OSRAM)
JP (1) JP2008516922A (OSRAM)
AR (1) AR051391A1 (OSRAM)
AT (1) ATE387202T1 (OSRAM)
DE (1) DE602005005080T2 (OSRAM)
DK (1) DK1802307T3 (OSRAM)
ES (1) ES2303280T3 (OSRAM)
HR (1) HRP20080227T3 (OSRAM)
PL (1) PL1802307T3 (OSRAM)
PT (1) PT1802307E (OSRAM)
SI (1) SI1802307T1 (OSRAM)
WO (1) WO2006040192A1 (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0324159D0 (en) 2003-10-15 2003-11-19 Glaxo Group Ltd Novel compounds
KR20090024811A (ko) 2006-06-23 2009-03-09 아보트 러보러터리즈 히스타민 h3 수용체 조절제로서의 사이클로프로필 아민 유도체
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
TW200902007A (en) * 2007-05-25 2009-01-16 Astrazeneca Ab Spirocyclopropyl piperidine derivatives
KR101588466B1 (ko) 2007-08-22 2016-01-25 아스트라제네카 아베 시클로프로필 아미드 유도체
TW200918527A (en) 2007-09-06 2009-05-01 Glaxo Group Ltd Piperazine derivative having affinity for the histamine H3 receptor
MX2010008700A (es) 2008-02-22 2010-08-30 Hoffmann La Roche Moduladores de beta-amiloide.
US8691804B2 (en) 2008-05-08 2014-04-08 Evotec Ag Azetidines and cyclobutanes as histamine H3 receptor antagonists
US8236792B2 (en) 2008-05-23 2012-08-07 Janssen Pharmaceutica Nv Substituted pyrrolidine amides as modulators of the histamine H3 receptor
AU2009278838B2 (en) * 2008-08-06 2013-07-25 Pfizer Limited Diazepine and diazocane compounds as MC4 agonists
AU2009301210B2 (en) 2008-10-09 2014-05-15 F. Hoffmann-La Roche Ag Modulators for amyloid beta
CN102209537A (zh) 2008-11-10 2011-10-05 弗·哈夫曼-拉罗切有限公司 杂环γ分泌酶调节剂
US20100130477A1 (en) * 2008-11-25 2010-05-27 Astrazeneca Ab Spirocyclobutyl Piperidine Derivatives
CA2751239C (en) 2009-02-02 2016-11-01 Adam James Davenport Azetidines as histamine h3 receptor antagonists
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
WO2011016559A1 (ja) * 2009-08-07 2011-02-10 武田薬品工業株式会社 複素環化合物およびその用途
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
US20110201623A1 (en) 2010-02-18 2011-08-18 Uczynski Michael A Crystalline Form Of A Cyclopropyl Benzamide Derivative
US8853390B2 (en) 2010-09-16 2014-10-07 Abbvie Inc. Processes for preparing 1,2-substituted cyclopropyl derivatives
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
EP2647377A1 (en) 2012-04-06 2013-10-09 Sanofi Use of an h3 receptor antagonist for the treatment of alzheimer's disease
WO2020163689A1 (en) 2019-02-08 2020-08-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Education 20-hete formation inhibitors
AU2023247609A1 (en) * 2022-03-31 2024-10-17 Bebetter Med Inc. 1,4-diheterocyclic substituted aromatic ring or aromatic heterocyclic compound and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000029984A (ko) * 1996-08-14 2000-05-25 사라 엔 람베쓰 치환된피리미딘유도체및이의약학적용도
DE10034338C2 (de) * 2000-07-14 2002-06-20 Forschungszentrum Juelich Gmbh Mehrpoliges kaskadierendes Quardrupel-Bandpaßfilter auf der Basis dielektrischer Dual-Mode-Resonatoren
WO2003062234A1 (en) * 2002-01-23 2003-07-31 Yamanouchi Pharmaceutical Co., Ltd. Quinoxaline compounds
JP2006505590A (ja) * 2002-10-23 2006-02-16 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒスタミンh3受容体調節物質としてのフェニルピペリジンおよびフェニルピロリジン
MXPA05011352A (es) * 2003-04-23 2005-11-28 Glaxo Group Ltd Derivados de piperazina y su uso para el tratamiento de enfermedades neurologicas y psiquiatricas.

Also Published As

Publication number Publication date
DE602005005080T2 (de) 2009-02-26
HRP20080227T3 (hr) 2008-06-30
WO2006040192A1 (en) 2006-04-20
PL1802307T3 (pl) 2008-07-31
ES2303280T3 (es) 2008-08-01
EP1802307B1 (en) 2008-02-27
DE602005005080D1 (de) 2008-04-10
US20080045506A1 (en) 2008-02-21
ATE387202T1 (de) 2008-03-15
SI1802307T1 (sl) 2008-08-31
PT1802307E (pt) 2008-06-06
EP1802307A1 (en) 2007-07-04
AR051391A1 (es) 2007-01-10
DK1802307T3 (da) 2008-06-30

Similar Documents

Publication Publication Date Title
JP2008516922A (ja) ヒスタミン受容体リガンドとしてのピロリジン誘導体
JP4824567B2 (ja) 新規化合物
KR102082331B1 (ko) Cot 조정제로서의 6-아미노-퀴놀린-3-카르보니트릴
KR20050121268A (ko) 피페라진 유도체 및 신경적 및 정신적 질병의 치료를 위한그의 용도
JP2007514690A (ja) ヒスタミンh3アンタゴニストとしてのベンズアゼピン誘導体
CN101277934A (zh) 使代谢型谷氨酸-受体-增效的异吲哚酮
JP2008509955A (ja) ヒスタミンh3受容体のアンタゴニストおよび/または逆アゴニストとしてのテトラヒドロベンズアゼピン
US7638631B2 (en) Methylene dipiperidine derivatives
US20060247227A1 (en) Substituted piperidines as histamine h3 receptor ligands
JP2008502644A (ja) ヒスタミンh3アンタゴニストとしての3−シクロアルキルベンズアゼピン
JP5145218B2 (ja) ヒスタミンh3アンタゴニストとしてのピラゾロ[3,4−d]アゼピン誘導体
KR20070091007A (ko) 인데닐 유도체 및 신경계 장애의 치료를 위한 이들의 용도
US20080009479A1 (en) Tetrahydrobenzazepines as Histamine H3 Receptor Ligands
KR20070113225A (ko) 히스타민 h3 수용체에 대해 친화성을 갖는 융합된 티아졸유도체
CN101115721A (zh) 茚基衍生物和它们在治疗神经疾病中的用途
WO2004056821A2 (en) Quinolizidine derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081010

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081010

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20101210